Source comparison
CJC-1295 no DAC & Ipamorelin vs Hexarelin: Research Application Comparison
GH Peak Magnitude 200–250% of baseline, sustained 90–120 minutes 400–700% of baseline, peaks at 30 minutes Hexarelin produces higher acute spikes but CJC/Ipa maintains physiological range. Better for metabolic studies requiring stable elevation Receptor Desens
This comparison does not assign a generated winner or score.
- GH Peak Magnitude
- 200–250% of baseline, sustained 90–120 minutes
- 400–700% of baseline, peaks at 30 minutes
- Hexarelin produces higher acute spikes but CJC/Ipa maintains physiological range. Better for metabolic studies requiring stable elevation
- Receptor Desensitization
- Minimal. 88% response retained at 24 weeks
- Severe. 60% reduction by week 12
- CJC/Ipa suitable for protocols >12 weeks; Hexarelin requires cycling or washout
- Cortisol/Prolactin Effect
- None. Ipamorelin is cortisol-neutral
- Moderate cortisol elevation (15–25% above baseline)
- CJC/Ipa eliminates confounding endocrine variables in multi-system studies
- Dosing Frequency
- 3× weekly maintains consistent levels
- Daily or twice-daily due to short half-life
- CJC/Ipa reduces handling frequency and injection-site irritation in long-term models
- Cost Per Week (Research Grade)
- Approximately $45–65 for combined vials
- Approximately $30–50 for single peptide
- Hexarelin cheaper upfront but requires dose escalation; CJC/Ipa cost-stable across study duration
- Best Research Context
- Longitudinal metabolic studies, body composition research, sustained anabolic investigation
- Acute GH response studies, receptor pharmacology research, short-duration protocols
- Choose based on study timeline. CJC/Ipa for anything beyond 10 weeks, Hexarelin for acute-phase work